New drug INI-4001 takes on advanced cancers in early trial

NCT ID NCT06302426

First seen Jan 24, 2026 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-phase study tests a new drug called INI-4001, alone or with standard immunotherapy, in people with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 50 adults with various cancers that cannot be cured with current treatments will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cabrini Hospital

    RECRUITING

    Malvern, Victoria, 3144, Australia

    Contact Email: •••••@•••••

    Contact

  • Southern Oncology Clinical Research Unit

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Border Cancer Hospital

    RECRUITING

    Albury, New South Wales, 2640, Australia

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.